EICHORPublic-registry trials using ITCA 650 Osmotic Mini Pump 20/60 mcg/day that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
ITCA 650 Osmotic Mini Pump 20/60 mcg/day appears in 1 registered trial Eichor's radar has found, sponsored by Intarcia Therapeutics, the most recent registered as Phase 3, with a planned enrollment of 136. Registered timeline: 2015–2017. The registry holds 11,826 registered studies for Diabetes Mellitus, Type 2.
| Trial | Sponsor | Condition | Phase | Sites |
| Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide | Intarcia Therapeutics | Diabetes Mellitus, Type 2 | PHASE3 | 36 |
| Status | Completed · planned start 2015-12 |
| Primary completion | 2017-10 |
| Enrollment target | 136 participants |
| Design | Randomized · Parallel · Phase 3 · 2 arms |
| Who it enrolls | All sexes · 18 Years and older — full criteria are on the study record |
| Locations | 36 listed in United States |
All fields verbatim from the ClinicalTrials.gov record for NCT02638805.
| First registered study | December 2015 — NCT02638805 (Intarcia Therapeutics) |
| Registered studies matching this name | 4 all-time · 0 currently recruiting |
Source: ClinicalTrials.gov, the public trial registry.
The public registry holds 11,826 registered studies for Diabetes Mellitus, Type 2. Compounds appearing across the 200 most recently updated registry entries:
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Trialed alongside
← Eichor home · All tracked trials · Diabetes Mellitus, Type 2 studies · Weekly briefs
